[go: up one dir, main page]

WO2010011926A3 - Nouveau co-cristal de bétaïne d'épalrestat - Google Patents

Nouveau co-cristal de bétaïne d'épalrestat Download PDF

Info

Publication number
WO2010011926A3
WO2010011926A3 PCT/US2009/051693 US2009051693W WO2010011926A3 WO 2010011926 A3 WO2010011926 A3 WO 2010011926A3 US 2009051693 W US2009051693 W US 2009051693W WO 2010011926 A3 WO2010011926 A3 WO 2010011926A3
Authority
WO
WIPO (PCT)
Prior art keywords
novel betaine
betaine cocrystal
cocrystal
novel
epalrestat
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2009/051693
Other languages
English (en)
Other versions
WO2010011926A2 (fr
Inventor
Isabel Kalofonos
Patrick G. Stahly
William Martin-Doyle
Dimitris Kalofonos
Jeffrey S. Stults
Travis L. Houston
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bionevia Pharmaceuticals Inc
Original Assignee
Bionevia Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bionevia Pharmaceuticals Inc filed Critical Bionevia Pharmaceuticals Inc
Priority to EP09801070A priority Critical patent/EP2340245A4/fr
Priority to EA201100246A priority patent/EA018905B1/ru
Publication of WO2010011926A2 publication Critical patent/WO2010011926A2/fr
Publication of WO2010011926A3 publication Critical patent/WO2010011926A3/fr
Priority to US13/013,786 priority patent/US8697735B2/en
Anticipated expiration legal-status Critical
Priority to US14/251,039 priority patent/US9447056B2/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/25—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids with polyoxyalkylated alcohols, e.g. esters of polyethylene glycol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/36—Sulfur atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

Cette invention concerne un nouveau co-cristal de bétaïne d'acide 5-[(lZ,2E)-2-méthyl-3-phénylpropénylidène]-4-oxo-2-thioxo-3- thiazolidineacétique. La préparation et la caractérisation du nouveau co-cristal de bétaïne selon divers modes de réalisation de l'invention sont décrites. L'invention concerne également des compositions pharmaceutiques contenant le nouveau co-cristal de bétaïne et l'utilisation de ce dernier en thérapie pour le traitement et/ou la prévention de diverses affections, comprenant le traitement et/ou la prévention des complications diabétiques, le traitement et/ou la prévention de l'homocystinurie, la réduction des taux sériques d'homocystéine, l'inhibition de l'aldose réductase, et la cardioprotection chez les patients non diabétiques.
PCT/US2009/051693 2008-07-25 2009-07-24 Nouveau co-cristal de bétaïne d'épalrestat Ceased WO2010011926A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP09801070A EP2340245A4 (fr) 2008-07-25 2009-07-24 Nouveau co-cristal de bétaïne d'épalrestat
EA201100246A EA018905B1 (ru) 2008-07-25 2009-07-24 Новый бетаиновый сокристалл эпалрестата
US13/013,786 US8697735B2 (en) 2008-07-25 2011-01-25 Solid forms of epalrestat
US14/251,039 US9447056B2 (en) 2008-07-25 2014-04-11 Solid forms of epalrestat

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8361908P 2008-07-25 2008-07-25
US61/083,619 2008-07-25

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/047060 Continuation-In-Part WO2009152347A2 (fr) 2008-06-13 2009-06-11 Formes cristallines de chlorhydrate de zotépine

Related Child Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2009/051687 Continuation-In-Part WO2010011922A2 (fr) 2008-07-25 2009-07-24 Nouveaux sels cristallins d’epalrestat
US13/013,786 Continuation-In-Part US8697735B2 (en) 2008-07-25 2011-01-25 Solid forms of epalrestat

Publications (2)

Publication Number Publication Date
WO2010011926A2 WO2010011926A2 (fr) 2010-01-28
WO2010011926A3 true WO2010011926A3 (fr) 2010-05-27

Family

ID=41570882

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/051693 Ceased WO2010011926A2 (fr) 2008-07-25 2009-07-24 Nouveau co-cristal de bétaïne d'épalrestat

Country Status (3)

Country Link
EP (1) EP2340245A4 (fr)
EA (1) EA018905B1 (fr)
WO (1) WO2010011926A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8697735B2 (en) 2008-07-25 2014-04-15 Bionevia Pharmaceuticals, Inc. Solid forms of epalrestat
WO2010028132A2 (fr) 2008-09-06 2010-03-11 Bionevia Pharmaceuticals, Inc. Nouveaux co-cristaux de choline et d'épalrestat
RU2013135224A (ru) 2011-01-20 2015-03-10 Бионевиа Фармасьютикалс Инк. Композиции с модифицированным высвобождением эпалрестата или его производных и способы их использования
ITMI20120586A1 (it) 2012-04-11 2013-10-12 Milano Politecnico Co-cristalli di 3-iodiopropinil butilcarbammato
CN113277962B (zh) * 2021-06-01 2023-02-07 天津大学 依帕司他-二甲双胍盐水合物及其制备方法和应用
CN113336718B (zh) * 2021-06-01 2023-02-28 天津大学 依帕司他-二甲双胍盐及其制备方法和应用
CN115925650B (zh) * 2022-12-13 2023-08-01 山东达因海洋生物制药股份有限公司 一种依帕司他共晶及其制备方法和应用
CN115947699B (zh) * 2023-01-16 2024-01-19 威海海洋职业学院 以烟酰胺为前驱体的依帕司他共晶及其制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4831045A (en) * 1980-08-22 1989-05-16 Ono Pharmaceutical Co., Ltd. Rhodanine derivatives, process for their preparation, and aldose reductase inhibitor containing the rhodanine derivatives as active ingredient
US20050181041A1 (en) * 2003-12-09 2005-08-18 Medcrystalforms, Llc Method of preparation of mixed phase co-crystals with active agents

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003272270A1 (en) * 2003-02-28 2004-09-28 The Regents Of The University Of Michigan Pharmaceutical co-crystal compositions of drugs such as carbamazeptine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
JP4892915B2 (ja) * 2005-10-04 2012-03-07 大日本印刷株式会社 エパルレスタット製造法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4831045A (en) * 1980-08-22 1989-05-16 Ono Pharmaceutical Co., Ltd. Rhodanine derivatives, process for their preparation, and aldose reductase inhibitor containing the rhodanine derivatives as active ingredient
US20050181041A1 (en) * 2003-12-09 2005-08-18 Medcrystalforms, Llc Method of preparation of mixed phase co-crystals with active agents

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
AMY LAWSON-YUEN ET AL.: "The use of betaine in the treatment of elevated homocysteine.", MOLECULAR GENETICS AND METABOLISM., vol. 88, no. 3, 2006, pages 201 - 207, XP024947075 *
ENOKA P. WIJEKOON ET AL.: "Homocysteine Metabolism in ZDF (Type 2) Diabetic Rats.", DIABETES., vol. 5, no. 11, 2005, pages 3245 - 3251, XP008135285 *
See also references of EP2340245A4 *

Also Published As

Publication number Publication date
EA018905B1 (ru) 2013-11-29
EP2340245A4 (fr) 2011-09-28
EP2340245A2 (fr) 2011-07-06
EA201100246A1 (ru) 2011-10-31
WO2010011926A2 (fr) 2010-01-28

Similar Documents

Publication Publication Date Title
WO2010028132A3 (fr) Nouveaux co-cristaux de choline et d'épalrestat
WO2010011926A3 (fr) Nouveau co-cristal de bétaïne d'épalrestat
WO2007127273A3 (fr) Procédés et compositions permettant de modifier la fonction cellulaire
WO2010001169A3 (fr) Composés chimiques 251
WO2008108957A3 (fr) Dérivés pipéridines et leurs procédés d'utilisation
WO2007084314A3 (fr) MODULATEURS de la 11-ß HYDROXYSTEROIDE DESHYDROGENASE DE TYPE 1, LEURS COMPOSITIONS PHARMACEUTIQUES ET LEURS PROCEDES D'UTILISATION
WO2008108958A3 (fr) Dérivés de benzimidazole et leurs procédés d'utilisation
WO2008033562A3 (fr) Composés inhibiteurs de kinases
WO2007103719A3 (fr) MODULATEURS DE LA 11-β-HYDROXYSTÉROÏDE DÉSHYDROGÉNASE DE TYPE 1, LEURS COMPOSITIONS PHARMACEUTIQUES ET LEURS PROCÉDÉS D'UTILISATION
WO2007061661A3 (fr) Inhibiteurs de la 11-beta-hydroxy steroide deshydrogenase de type 1
WO2009091550A8 (fr) Dérivés de 2,3-dihydroimidazo [1,2-c] quinazoline à substitution sulfone utilisés pour traiter des troubles hyperproliférants et des maladies associées à l'angiogénèse
WO2006096439A3 (fr) Compositions pharmaceutiques destinees au traitement et/ou a la prevention de la schizophrenie et de maladies associees
WO2008054454A3 (fr) Dérivés hétérocycliques contenant de l'azote, compositions pharmaceutiques, et leurs procédés d'utilisations en tant qu'agents antiviraux
WO2009109618A3 (fr) Nouveaux dérivés de 1-benzyl-3-hydroxyméthylindazole et leur utilisation dans le traitement des maladies basées sur l’expression de mcp-1, cx3cr1 et p40
WO2010135530A3 (fr) Composés, compositions et procédés pour moduler des taux d'acide urique
WO2009109616A3 (fr) Nouveaux dérivés de 1-benzyl-3-hydroxyméthylindazole et leur utilisation dans le traitement des maladies basées sur l'expression de mcp-1, cx3cr1 et p40
WO2009022899A8 (fr) Gel à base de pirfénidone
MY182983A (en) A skin external composition comprising a salt and sugar as active ingredients for preventing and treating vaginosis and the use thereof
WO2009045291A3 (fr) Stabilisateurs de cellules mast dans le traitement de l'obésité
WO2009109654A8 (fr) Nouveaux dérivés de 1-benzyl-3-hydroxyméthylindazole et leur utilisation dans le traitement des maladies basées sur l’expression de mcp-1 et cx3cr1
WO2010090494A3 (fr) Utilisation médicale de dérivés d'acide 5-benzylaminosalicylique ou de sels correspondants
WO2008112773A3 (fr) Droxidopa et composition pharmaceutique de celle-ci pour le traitement de l'hypotension véhiculée par voie neurale
WO2009062576A3 (fr) Nouveaux dérivés de benzimidazole-dihydrothiadiazinone en tant que des inhibiteurs de la fructose-1,6-bisphosphatase, et compositions pharmaceutiques les comprenant
WO2007075695A3 (fr) Utilisation de derives de sulfamide heterocyclique benzo-fusionne pour le traitement de la manie et du trouble bipolaire
WO2010011922A3 (fr) Nouveaux sels cristallins d’epalrestat

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09801070

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 201100246

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 2009801070

Country of ref document: EP